Oppenheimer initiated coverage on Sutro Biopharma with a new price target
$STRO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Oppenheimer initiated coverage of Sutro Biopharma with a rating of Outperform and set a new price target of $10.00